share_log

Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M

Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M

Pyxis Oncology以800萬美元的價格向諾華完成了向諾華出售其從Beovu（brolucizumab-DBLL）商業化中獲得的特許權使用費和另一項資產
Benzinga ·  03/27 19:39

Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M

Pyxis Oncology以800萬美元的價格向諾華完成了向諾華出售其從Beovu（brolucizumab-DBLL）商業化中獲得的特許權使用費和另一項資產

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論